Download PDF
Thromb Haemost 1996; 76(05): 738-742
DOI: 10.1055/s-0038-1650653
Original Article
Schattauer GmbH Stuttgart

Interleukin-6 Stimulates Coagulation, not Fibrinolysis, in Humans

Jacqueline M L Stouthard
1   The Department of Internal Medicine, Department of Endocrinology and Metabolism, all from the Academic Medical Centre, University of Amsterdam, The Netherlands
5   Metabolic Research Group, Department of Endocrinology and Metabolism, all from the Academic Medical Centre, University of Amsterdam, The Netherlands
,
Marcel Levi
1   The Department of Internal Medicine, Department of Endocrinology and Metabolism, all from the Academic Medical Centre, University of Amsterdam, The Netherlands
2   Centre for Haemostasis, Thrombosis, Atherosclerosis, and Inflammation Research, Department of Endocrinology and Metabolism, all from the Academic Medical Centre, University of Amsterdam, The Netherlands
,
C Erik Hack
3   Department of Autoimmune Diseases, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands
,
Cees H N Veenhof
4   Department of Medical Oncology , Department of Endocrinology and Metabolism, all from the Academic Medical Centre, University of Amsterdam, The Netherlands
,
Hans A Romijn
5   Metabolic Research Group, Department of Endocrinology and Metabolism, all from the Academic Medical Centre, University of Amsterdam, The Netherlands
,
Hans P Sauerwein
5   Metabolic Research Group, Department of Endocrinology and Metabolism, all from the Academic Medical Centre, University of Amsterdam, The Netherlands
,
Tom van der Poll
1   The Department of Internal Medicine, Department of Endocrinology and Metabolism, all from the Academic Medical Centre, University of Amsterdam, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 08 February 1996

Accepted after resubmission 19 June 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The role of IL-6 as a mediator of haemostatic changes during severe inflammation is controversial. To assess the effect of IL-6 on haemostasis we conducted a controlled cross-over study in eight patients with metastatic renal cell cancer. In all subjects coagulation and fibrinolysis were monitored during and after a 4-h infusion of either 150 μg recombinant human (rh) IL-6, or during infusion of saline (control study). Mean maximum IL-6 concentrations were 1418.0 ± 755.8 pg/ml. Compared to the control study, rhIL-6 induced activation of coagulation as reflected by a 190 ± 55% increase in the plasma levels of thrombin-antithrombin III complexes (p <0.001) and by a 24 ± 11% increase in the plasma levels of in the prothrombin activation fragment F1 + 2 (p <0.001). In contrast, fibrinolysis was not affected. We conclude that in severe inflammation IL-6 may contribute to the activation of coagulation, whereas other factors mediate changes in fibrinolysis.

 

  • References

  • 1 Marder VJ, Martin SE, Francis CW, Colman RW. Consumptive thrombo-hemorrhagic disorders. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice Colman RW, Hirsch J, Marder VJ, Salzman EW. eds J. B. Lippincott Company; Philadelphia: 1987: 975-1015
  • 2 Levi M, ten Cate H, Van der Poll T, Van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979
    CrossrefPubMedGoogle Scholar
  • 3 Van der Poll T, Büller HR, ten Cate H, Wortel CH, Bauer KA, Van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, Ten Cate JW. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-1627
    CrossrefPubMedGoogle Scholar
  • 4 Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989; 74: 165-172
    PubMedGoogle Scholar
  • 5 Van der Poll T, Levi M, Büller HR, Van Deventer SJH, De Boer JP, Hack CE, ten Cate JW. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 729-732
    CrossrefPubMedGoogle Scholar
  • 6 Silverman P, Goldsmith GH, Spitzer TR, Rehmus EH, Berger NA. Effect of tumor necrosis factor on the human fibrinolytic system. J Clin Oncol 1990; 8: 468-475
    CrossrefPubMedGoogle Scholar
  • 7 van Hinsbergh VWM, Bauer KA, Kooistra T, Kuft C, Dooijeward G, Sherman ML, Nieuwenhuizen W. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990; 76: 2284-2289
    PubMedGoogle Scholar
  • 8 Logan TH, Virji MA, Gooding WE, Bontempo FA, Ernstoff MS, Kirkwood JM. Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor. J Natl Cancer Inst 1992; 84: 1802-1810
    CrossrefPubMedGoogle Scholar
  • 9 Van der Poll T, Levi M, Van Deventer SJH, Ten Cate H, Haagmans BL, Biemond BJ, Büller HR, Hack CE, Ten Cate JW. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994; 83: 446-451
    PubMedGoogle Scholar
  • 10 Hinshaw LB, Tekamp-Olson P, Chang ACK, Lee PA, Taylor Jr FB, Murray CK, Peer GT, Emerson Jr TE, Passey B, Kuo GC. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF). Circ Shock 1990; 30: 279-292
    PubMedGoogle Scholar
  • 11 Le J, Vilcek J. Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein sequence. Lab Invest 1989; 61: 588-602
    PubMedGoogle Scholar
  • 12 Van der Poll T, Levi M, Hack CE, Ten Cate H, Van Deventer SJH, Eeren-berg AJM, De Groot ER, Jansen J, Gallati H, Büller HR, ten Cate JW, Aarden LA. Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-1259
    CrossrefPubMedGoogle Scholar
  • 13 Heremans H, Dillen C, Put W, Van Damme J, Billiau A. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol 1992; 22: 2395-2401
    CrossrefPubMedGoogle Scholar
  • 14 Helle M, Boeije L, de Groot ER, De Vos A, Aarden LA. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids and sera. J Immunol Methods 1991; 138: 47-56
    PubMedGoogle Scholar
  • 15 Van Zonneveld AJ, Veerman H, Brakenhof JP, Aarden LA, Cajot JF, Pannekoek H. Mapping of epitopes on human tissue plasminogen activator with recombinant deletion mutant proteins. Thromb Haemost 1987; 57: 82-86
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Levi M, De Boer JP, Roem D, Ten Cate JW, Hack CE. Plasminogen activation in vivo upon intravenous infusion of DDAVP: quantative assessment of plasmin-alpha2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992; 67: 111-116
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 De Boer JP, Creasey AA, Chang A, Roem D, Brouwer MC, Eerenberg AJM, Hack CE, Taylor Jr FB. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli . Circ Shock 1993; 39: 59-67
    PubMedGoogle Scholar
  • 18 De Boer JP, Abbink JJ, Brouwer MC, Meijer C, Roem D, Voom GP, Lambers JWJ, Van Mourik JA, Hack CE. PAI-1 synthesis in the human hepatoma cell line HepG2 is increased by cytokines - Evidence that the liver contributes to acute phase behaviour of PAI-1. Thromb Haemost 1991; 65: 181-185
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Verheijen HJ, Mullaart E, Chang GTG, Kluft C, Wijnaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurement in plasma. Thromb Haemost 1982; 48: 266-269
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Stouthard JML, Van der Poll T, Endert E, Bakker PJM, Veenhof CHN, Sauerwein HP, Romijn JA. The acute and chronic effects of interleukin-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab 1994; 79: 1342-1346
    PubMedGoogle Scholar
  • 21 Stouthard JML, Goey H, De Vries EGE, De Mulder PH, Groenewegen A, Pronk L, Stoter G, Sauerwein HP, Bakker PJM, Veenhof CHN. Recombinant humaninterleukin-6 in metastatic renal cell cancer: A phase II trial. Br J Cancer in press
    PubMedGoogle Scholar
  • 22 Edwards EL, Rickies FR. The role of leukocytes in the activation of blood coagulation. Semin Hematol 1992; 29: 202-212
    PubMedGoogle Scholar
  • 23 Mestries J-C, Kruithof EKO, Gascon M-P, Herodin F, Agay D, Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur Cytokine Netw 1994; 5: 275-281
    PubMedGoogle Scholar
  • 24 Lowry SF, Calvano SE, Van der Poll T. Measurement of inflammatory mediators in clinical sepsis. In: Sibbald WJ, Vincent JL. eds. Clinical trials for the treatment of sepsis; Springer-Verlag: 1995: 86-105
  • 25 Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex - pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169: 333-338
    CrossrefPubMedGoogle Scholar
  • 26 Patel RT, Deen KI, Youngs D, Warwick J, Keighley MRB. Interleukin-6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surgery 1994; 81: 1306-1308
    CrossrefPubMedGoogle Scholar
  • 27 Van Deventer SJH, Büller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990; 76: 2520-2526
    CrossrefPubMedGoogle Scholar
  • 28 Taylor Jr FB, Chang A, Peer G, Li A, Burstein S. IL-6 amplifies the coagulopathic response of the baboon to E. Coli. Thromb Haemost 1995; 73: 1433 (abstract)
    PubMedGoogle Scholar
  • 29 Levi M, Ten Cate H, Bauer KA, Van der Poll T, Edgington TS, Büller HR, van Deventer SJH, Hack CE, Ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifyl-lin or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120
    CrossrefPubMedGoogle Scholar
  • 30 Taylor Jr FB, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS, Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134
    PubMedGoogle Scholar
  • 31 Creasey AA, Chang ACK, Feigen L, Wün TC, Taylor Jr FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2860
    CrossrefPubMedGoogle Scholar
  • 32 Cermak J, Key NS, Bach RR, Balia J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520
    CrossrefPubMedGoogle Scholar
  • 33 Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after major surgery. Br J Surg 1992; 79: 757-760
    CrossrefPubMedGoogle Scholar